Suppr超能文献

相似文献

1
Heteroresistance to cephalosporins and penicillins in Acinetobacter baumannii.
J Clin Microbiol. 2012 Mar;50(3):721-6. doi: 10.1128/JCM.05085-11. Epub 2011 Dec 21.
4
Heteroresistance to meropenem in carbapenem-susceptible Acinetobacter baumannii.
J Clin Microbiol. 2009 Dec;47(12):4055-9. doi: 10.1128/JCM.00959-09. Epub 2009 Oct 14.
5
Prevalence and Characterization of Integrons in Multidrug Resistant Acinetobacter baumannii in Eastern China: A Multiple-Hospital Study.
Int J Environ Res Public Health. 2015 Aug 21;12(8):10093-105. doi: 10.3390/ijerph120810093.
6
Characterisation of successive Acinetobacter baumannii isolates from a deceased haemophagocytic lymphohistiocytosis patient.
Int J Antimicrob Agents. 2017 Jan;49(1):102-106. doi: 10.1016/j.ijantimicag.2016.09.024. Epub 2016 Nov 8.
8
Methods to Evaluate Colistin Heteroresistance in Acinetobacter baumannii.
Methods Mol Biol. 2019;1946:39-50. doi: 10.1007/978-1-4939-9118-1_4.
10
Imipenem heteroresistance induced by imipenem in multidrug-resistant Acinetobacter baumannii: mechanism and clinical implications.
Int J Antimicrob Agents. 2011 Apr;37(4):302-8. doi: 10.1016/j.ijantimicag.2010.12.015. Epub 2011 Feb 25.

引用本文的文献

2
Clinical characteristics, molecular epidemiology and mechanisms of colistin heteroresistance in complex.
Front Cell Infect Microbiol. 2025 Mar 6;15:1536058. doi: 10.3389/fcimb.2025.1536058. eCollection 2025.
3
Essential Oil to Enhance the Effect of Imipenem against Axenic and Co-Cultures of and .
Antibiotics (Basel). 2024 May 14;13(5):444. doi: 10.3390/antibiotics13050444.
4
Cephalosporin resistance, tolerance, and approaches to improve their activities.
J Antibiot (Tokyo). 2024 Mar;77(3):135-146. doi: 10.1038/s41429-023-00687-y. Epub 2023 Dec 19.
5
Antimicrobial resistance patterns of and isolated from dogs presented at a veterinary academic hospital in South Africa.
Vet World. 2023 Sep;16(9):1880-1888. doi: 10.14202/vetworld.2023.1880-1888. Epub 2023 Sep 17.
7
Antibiotic Resistance Profiles, Molecular Mechanisms and Innovative Treatment Strategies of .
Microorganisms. 2020 Jun 21;8(6):935. doi: 10.3390/microorganisms8060935.
8
Deciphering colistin heteroresistance in Acinetobacter baumannii clinical isolates from Wenzhou, China.
J Antibiot (Tokyo). 2020 Jul;73(7):463-470. doi: 10.1038/s41429-020-0289-2. Epub 2020 Mar 9.
9
Mechanisms and clinical relevance of bacterial heteroresistance.
Nat Rev Microbiol. 2019 Aug;17(8):479-496. doi: 10.1038/s41579-019-0218-1. Epub 2019 Jun 24.
10

本文引用的文献

1
Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae.
J Antimicrob Chemother. 2011 Apr;66(4):946-7. doi: 10.1093/jac/dkr007. Epub 2011 Jan 25.
3
An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
Antimicrob Agents Chemother. 2010 Dec;54(12):5222-33. doi: 10.1128/AAC.00437-10. Epub 2010 Sep 13.
4
Prevalence and characteristics of ertapenem-nonsusceptible Escherichia coli in a Taiwanese university hospital, 1999 to 2007.
Eur J Clin Microbiol Infect Dis. 2010 Nov;29(11):1417-25. doi: 10.1007/s10096-010-1020-1. Epub 2010 Aug 11.
5
Multiresistant Acinetobacter baumannii infections: epidemiology and management.
Curr Opin Infect Dis. 2010 Aug;23(4):332-9. doi: 10.1097/QCO.0b013e32833ae38b.
7
Treatment of Acinetobacter infections.
Clin Infect Dis. 2010 Jul 1;51(1):79-84. doi: 10.1086/653120.
8
Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance.
Int J Antimicrob Agents. 2010 Mar;35(3):219-26. doi: 10.1016/j.ijantimicag.2009.10.024. Epub 2010 Jan 4.
9
Heteroresistance to meropenem in carbapenem-susceptible Acinetobacter baumannii.
J Clin Microbiol. 2009 Dec;47(12):4055-9. doi: 10.1128/JCM.00959-09. Epub 2009 Oct 14.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验